drugset / Trial / NCT03809078
68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
RandomizedSequentialOpen-labelDiagnostic
Summary
The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance in patients with suspected prostate cancer.
Timeline
- Start
- 2019-01-14
- Primary completion
- 2022-03-08
- Completion
- 2022-03-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-PSMA-11 | Diagnostic / imaging agent | 3 mmol | Intravenous |
| Subject | 68Ga-PSMA-11 | Diagnostic / imaging agent | 7 mmol | Intravenous |
| Subject | 68Ga-RM2 | Diagnostic / imaging agent | 140 mbq | Intravenous |